# Eylea® (eylea) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/eylea

> The FDA approved Eylea® (eylea), sponsored by REGENERON PHARMACEUTICALS, INC. (REGN), on Apr 2026 for wet age-related macular degeneration.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Eylea® (eylea) |
| Codes |  |
| Sponsor | REGENERON PHARMACEUTICALS, INC. (REGN) https://sec-api.dev/companies/regn/catalysts |
| Indications | [macular edema](https://sec-api.dev/indications/macular-edema), [neovascular](https://sec-api.dev/indications/neovascular), [wet age-related macular degeneration](https://sec-api.dev/indications/wet-age-related-macular-degeneration), with rvo with up to every 8-week dosing |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Aug 2023: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2025-02-04, last confirmed 2025-02-04.
- Press release filed with the SEC (EX-99) (accession 0001804220-25-000007): "EYLEA HD was approved by the FDA in August 2023 and net product sales in 2024 were driven by the transition of patients from other anti-VEGF products, including EYLEA, as well as new patients naïve to anti-VEGF therapy." https://www.sec.gov/Archives/edgar/data/872589/000180422025000007/exhibit991q42024.htm

### Jan 2024: topline data readout

- Status: completed, positive. Date confidence: month. Indication: neovascular.
- First seen 2025-02-18, last confirmed 2025-06-23.
- Press release filed with the SEC (EX-99) (accession 0001171843-25-004011): "In January 2024 Alvotech announced positive top-line results from a confirmatory clinical study with AVT06 (AVT06-GL-C01) comparing the efficacy, safety, and immunogenicity of the proposed biosimilar to Eylea® in patients with neovascular (wet) AMD." https://www.sec.gov/Archives/edgar/data/1898416/000117184325004011/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-000882): "In January 2024, Alvotech announced positive top-line results from a confirmatory clinical study (AVT06-GL-C01) comparing the efficacy, safety, and immunogenicity of AVT06 with Eylea® in patients with neovascular (wet) AMD." https://www.sec.gov/Archives/edgar/data/1898416/000117184325000882/exh_991.htm

### Q1 2025: NDA/BLA submission

- Status: scheduled. Date confidence: quarter.
- First seen 2025-01-13, last confirmed 2025-01-13.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-002826): "The Company plans to submit a sBLA for EYLEA HD for every four-week dosing and for retinal vein occlusion (RVO) in the first quarter of 2025 to potentially maximize dosing flexibility and address more retinal diseases." https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-1.htm

### April 20, 2025: PDUFA date

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2025-01-13, last confirmed 2025-01-13.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-002826): "Longer term data in wet age-related macular degeneration (wAMD) and diabetic macular edema (DME) are under FDA review with a PDUFA date of April 20, 2025 to potentially extend dosing intervals for EYLEA HD up to every-24 weeks." https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001804220-25-000020): "•The FDA issued a Complete Response Letter (CRL) for the EYLEA HD pre-filled syringe on April 23, 2025." https://www.sec.gov/Archives/edgar/data/872589/000180422025000020/exhibit991q12025.htm

### April 23, 2025: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2025-04-29, last confirmed 2025-08-01.
- Press release filed with the SEC (EX-99) (accession 0001804220-25-000020): "•The FDA issued a Complete Response Letter (CRL) for the EYLEA HD pre-filled syringe on April 23, 2025." https://www.sec.gov/Archives/edgar/data/872589/000180422025000020/exhibit991q12025.htm
- SEC Form 10-Q (accession 0000872589-25-000019): "The FDA issued a CRL for the EYLEA HD pre-filled syringe in April 2025, and the FDA subsequently accepted the Company's resubmission of its regulatory application for the EYLEA HD pre-filled syringe." https://www.sec.gov/Archives/edgar/data/872589/000087258925000019/regn-20250630.htm

### Aug 2025: PDUFA date

- Status: completed, complete response letter. Date confidence: month. Indication: macular edema.
- First seen 2025-08-01, last confirmed 2025-08-01.
- Press release filed with the SEC (EX-99) (accession 0000872589-25-000017): "•The Company now expects regulatory approvals to be delayed for its currently pending FDA applications for EYLEA HD (pre-filled syringe, every-four-week dosing, and for the treatment of macular edema following retinal vein occlusion), which have PDUFA dates in August 2025." https://www.sec.gov/Archives/edgar/data/872589/000087258925000017/exhibit991q22025.htm
- SEC Form 10-Q (accession 0000872589-25-000019): "However, the Company now expects regulatory approvals to be delayed for its currently pending FDA applications for EYLEA HD (pre-filled syringe, every-four-week dosing, and for the treatment of macular edema following retinal vein occlusion), which have PDUFA dates in August 2025." https://www.sec.gov/Archives/edgar/data/872589/000087258925000019/regn-20250630.htm

### Nov 2025: FDA approval

- Status: completed, approved. Date confidence: month. Indication: with RVO with up to every 8-week dosing.
- First seen 2026-01-30, last confirmed 2026-01-30.
- Press release filed with the SEC (EX-99) (accession 0000872589-26-000004): "•In November 2025, the FDA approved EYLEA HD for the treatment of patients with RVO with up to every 8-week dosing after an initial monthly dosing period." https://www.sec.gov/Archives/edgar/data/872589/000087258926000004/exhibit991q42025.htm
- Press release filed with the SEC (EX-99) (accession 0000872589-26-000004): "•In December 2025, the FDA approved the addition of a new manufacturer to fill vials for EYLEA HD." https://www.sec.gov/Archives/edgar/data/872589/000087258926000004/exhibit991q42025.htm

### Nov 2025: PDUFA date

- Status: scheduled. Date confidence: month. Indication: macular edema.
- First seen 2025-10-28, last confirmed 2025-10-28.
- Press release filed with the SEC (EX-99) (accession 0000872589-25-000026): "There is also an sBLA under review by the FDA for EYLEA HD every-four-week dosing and for the treatment of macular edema following retinal vein occlusion (RVO), which has a target action date in late November 2025." https://www.sec.gov/Archives/edgar/data/872589/000087258925000026/exhibit991q32025.htm

### Apr 2026: FDA approval

- Status: completed, approved. Date confidence: month. Indication: wet age-related macular degeneration.
- First seen 2026-07-30, last confirmed 2026-07-30.
- Press release filed with the SEC (EX-99) (accession 0000872589-26-000023): "•In April 2026, the FDA approved the extension of dosing intervals for EYLEA HD up to every 20 weeks (5 months) for patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME) following one year of successful response based on visual and anatomic outcomes." https://www.sec.gov/Archives/edgar/data/872589/000087258926000023/exhibit991q22026.htm

## Same indication

- [PAVBLU® (aflibercept)](https://sec-api.dev/pdufa/aflibercept) (REGN)
- [Biosimilar](https://sec-api.dev/pdufa/biosimilar) (ALVO)
- [Lucentis® (ranibizumab)](https://sec-api.dev/pdufa/ranibizumab) (ABBV)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/eylea.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Eylea® (eylea) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/eylea

```bibtex
@misc{secapidev_pdufa_eylea_20261116,
  title        = {Eylea® (eylea) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/eylea}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_eylea_20261116","title":"Eylea® (eylea) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/eylea","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
